
News|Articles|October 8, 2012
FDA gives green light to ANDA for chewable diabetes tablet
FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
4 things to know about the Abarca/LucyRx merger
2
Healthcare's AI push is creating a new workforce challenge
3
EHR-based risk calculator reduces 3-year diabetes risk in patients with prediabetes
4
FDA expands Capvaxive indication to include adolescent patients at risk for pneumococcal disease
5

































